医学
肿瘤科
异柠檬酸脱氢酶
比例危险模型
内科学
危险分层
队列
预后变量
生存分析
脑瘤
回顾性队列研究
胶质母细胞瘤
外科
队列研究
预测模型
生物标志物
原发性肿瘤
总体生存率
胶质瘤
残余物
多元分析
试验预测值
辅助治疗
递归分区
临床决策
作者
Sam Ng,Fabien Almairac,Jérémy Deverdun,Amélie Darlix,Lydiane Mondot,Elisabeth Fabre,Suzanne Tran,Guillaume Herbet,Valérie Rigau,Emmanuelle Le Bars,Emmanuel Mandonnet,Hugues Duffau
出处
期刊:Neuro-oncology
[Oxford University Press]
日期:2026-11-03
卷期号:: noag277-
被引量:1
标识
DOI:10.1093/neuonc/noag277
摘要
BACKGROUND: Contemporary risk stratification of isocitrate dehydrogenase (IDH)-mutant lower-grade gliomas relies primarily on molecular characteristics and surgical tumor burden but does not capture dynamic tumor behavior. Our primary objective was to determine whether pretherapeutic tumor growth velocity (TGV) provides independent prognostic information for overall survival (OS) beyond established factors. METHODS: This multicenter retrospective study included 569 adults with grade 2-3 IDH-mutant gliomas from three French centers, comprising a development cohort (n = 440) and two external validation cohorts (n = 129). TGV was derived from automated, outcome-blinded volumetric analysis of serial preoperative MRI using mean diameter expansion and log-volume growth. Prognostic value was assessed using multivariable Cox regression, external validation, decision curve analysis, and exploratory random survival forests. RESULTS: During a median follow-up of 6.8 years, 73 deaths occurred in the development cohort. Higher TGV was independently associated with shorter overall survival after adjustment for age, sex, grade, 1p/19q status, and postoperative residual tumor volume (HR per 1-mm/year increase, 1.046; 95%CI, 1.011-1.083; P=.011), and was independently replicated externally (HR, 1.077; 95% CI, 1.005-1.153; P=.035). Findings were consistent using log-volume growth and after accounting for CDKN2A/B status. Adding TGV improved prognostic model fit (likelihood-ratio χ²=5.70; P=.017), with greatest incremental value in astrocytomas. Decision curve analysis demonstrated additional clinical utility, while survival forests identified TGV among the strongest survival predictors alongside 1p/19q status and postoperative residual tumor volume. CONCLUSIONS: Pretherapeutic TGV independently predicts survival beyond contemporary molecular and surgical factors in IDH-mutant lower-grade gliomas. This accessible MRI-derived biomarker may refine individualized risk stratification, particularly in astrocytoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI